MedTrace Logo

ASPIRIN Trial Belgium

NCT03464305 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2024-03-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether acetylsalicylic acid is effective on the recurrence and survival of colon cancer patients.

Conditions

Interventions

DRUG

acetylsalicylic acid

Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.

DRUG

Placebo

Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.

Sponsors & Collaborators

  • Kom Op Tegen Kanker

    collaborator OTHER

  • Anticancerfund

    collaborator UNKNOWN

  • University Hospital, Antwerp

    lead OTHER

Principal Investigators

  • Marc Peeters, Prof dr · University Hospital, Antwerp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-22
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03464305 on ClinicalTrials.gov